Clin2
NCT07422675Possibly a fitRecruiting

Study of a new treatment for Parkinson's with motor fluctuations

PARKINSON DISEASE (Disorder)Advanced Parkinson's Disease

Part of Brain & nervous system clinical trials.

This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
40 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • You are between 40 and 80 years old.
  • You have typical Parkinson's disease with clear 'off' periods where your symptoms return, and you take levodopa at least 3 to 4 times a day.
  • You have not had surgery for Parkinson's (like deep brain stimulation) or used a pump therapy (like Duopa or apomorphine).
  • You do not have significant heart disease, untreated depression, or a history of substance abuse.
  • You are willing to use reliable birth control during the study and for 3 months after, if needed.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07227896Not yet recruiting
Study of a new pump treatment for advanced Parkinson's

This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.

Boston, Massachusetts
NCT07432958Recruiting· Phase 2
Study of AP-472 with levodopa for Parkinson's motor fluctuations

This trial tests an experimental drug called AP-472, taken alongside your regular Parkinson's medications, to see if it can reduce the amount of "OFF" time you experience each day when symptoms return between doses of levodopa.

Little Rock, Arkansas
NCT07138560Recruiting· Phase 4
Study of IPX-203 for Parkinson's disease (BOOST-PD)

This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.

Cleveland, Ohio
NCT07514858Not yet recruiting· Phase 2
Lu AF28996 for Parkinson's Disease Motor Fluctuations

This trial tests a new medication called Lu AF28996 to help reduce the periods when Parkinson's symptoms worsen throughout the day (called 'OFF times'). If you have motor fluctuations that are predictable and affecting your daily life, this study might help you experience fewer of these difficult periods.

NCT07142044Recruiting· Phase 1/Phase 2
Testing EC5026 for Parkinson's disease

This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.

Sacramento, California
NCT05072015Not yet recruiting
Tracking second-line Parkinson treatments over time

This study follows people with Parkinson’s who have troublesome “ups and downs” or involuntary movements, and who need a device/infusion treatment like deep brain stimulation, an apomorphine pump, or a Duodopa pump. It helps doctors see how these second-line treatments are working in real life and what outcomes they produce.

Strasbourg

Hear when a new PARKINSON DISEASE (Disorder) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.